Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Viemed Healthcare (VMD) over the last 8 years, with Q3 2025 value amounting to $11.1 million.

  • Viemed Healthcare's Cash & Equivalents fell 197.41% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 197.41%. This contributed to the annual value of $17.5 million for FY2024, which is 3661.5% up from last year.
  • Latest data reveals that Viemed Healthcare reported Cash & Equivalents of $11.1 million as of Q3 2025, which was down 197.41% from $20.0 million recorded in Q2 2025.
  • In the past 5 years, Viemed Healthcare's Cash & Equivalents ranged from a high of $31.2 million in Q2 2021 and a low of $7.3 million during Q1 2024
  • Over the past 5 years, Viemed Healthcare's median Cash & Equivalents value was $17.5 million (recorded in 2024), while the average stood at $18.4 million.
  • Per our database at Business Quant, Viemed Healthcare's Cash & Equivalents surged by 26980.62% in 2021 and then tumbled by 6895.6% in 2024.
  • Over the past 5 years, Viemed Healthcare's Cash & Equivalents (Quarter) stood at $28.4 million in 2021, then plummeted by 40.46% to $16.9 million in 2022, then fell by 24.09% to $12.8 million in 2023, then skyrocketed by 36.62% to $17.5 million in 2024, then crashed by 36.58% to $11.1 million in 2025.
  • Its Cash & Equivalents was $11.1 million in Q3 2025, compared to $20.0 million in Q2 2025 and $10.2 million in Q1 2025.